Chronic Oral Polymeric Duodenal Exclusion Therapy Has Profound Metabolic Benefits in a T2D Rat Model and Affects Duodenal Morphological Enteroplasticity Similar to RYGB surgery: Implications for T2D Therapy

被引：0
|
作者：
Nimgaonkar, Ashish
Guerina, Florence
Kelleher, Shannon L.
Carlson, Taylor
Colbert, Kevin
Polomoscanik, Steven
Petersen, John S.
Habegger, Kirk M.
Pasricha, Pankaj J.
Fineman, Mark
Jozefiak, Thomas H.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-818-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
818-P
引用
收藏
页数：1
相关论文
共 22 条
  • [1] Profound Metabolic Benefits Observed in an Eight -Week GK Rat Study of a Novel Orally Administered Polymeric Duodenal Exclusion Therapy: Implications for Type 2 Diabetes (T2D) Therapy
    Nimgaonkar, Ashish
    Polomoscanik, Steven
    Pasricha, Pankaj J.
    Colbert, Kevin
    Jozefiak, Thomas H.
    Vora, Jiten
    Vieira, Marcela
    Carlson, Taylor
    Liu, Liansheng
    Kulkarni, Subhash
    Petersen, John S.
    DIABETES, 2021, 70
  • [2] Duodenal Targeting by Oral Pharmacologic Duodenal Exclusion Therapy for Treatment of Type 2 Diabetes (T2D)
    Nimgaonkar, Ashish
    Bryant, Christine
    Carlson, Taylor
    Guerina, Florence V.
    Colbert, Kevin
    Polomoscanik, Steven
    Petersen, John S.
    Jozefiak, Thomas H.
    Fineman, Mark
    DIABETES, 2023, 72
  • [3] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Bodyweight and Glucose in Patients with T2D
    Bryant, Christine
    Colbert, Kevin
    Petersen, John
    Jozefiak, Thomas
    Nimgaonkar, Ashish
    Fineman, Mark
    OBESITY, 2023, 31 : 39 - 39
  • [4] GLY-200 (Oral Pharmacologic Duodenal Exclusion) Reduces Appetite and Food Intake in Patients with T2D
    Bryant, Christine
    Nimgaonkar, Ashish
    Fineman, Mark
    OBESITY, 2023, 31 : 178 - 178
  • [5] Metabolic benefits of adding pioglitazone to patients with Type 2 diabetes (T2D) already optimized on insulin therapy
    Mattoo, V
    Eckland, D
    Widel, M
    Duran, S
    Fajardo, C
    Strand, J
    Knight, D
    Oakley, D
    Tan, M
    DIABETOLOGIA, 2004, 47 : A59 - A59
  • [6] Effect of Duodenal-Jejunal Bypass Surgery on Glucose Homeostasis and β-Cell Function in Overweight and Obese Subjects with Type 2 Diabetes (T2D)
    Fabbrini, Elisa
    Patterson, Bruce
    Schiavon, Carlos
    Correa, Jose
    Salles, Joao
    Wajchemberg, Bernardo
    Klein, Samuel
    Cohen, Ricardo
    DIABETES, 2011, 60 : A510 - A511
  • [7] Does Background T2D Therapy Modify the Benefits of Dapagliflozin in Heart Failure? Analysis of the DAPA-HF Trial
    Docherty, Kieran
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Kober, Lars
    Langkilde, Anna Maria
    Martinez, Felipe
    Bengtsson, Olof
    Demets, David L.
    Sjostrand, Mikaela
    Sabatine, Marc S.
    Solomon, Scott
    Jhund, Pardeep
    Mcmurray, John J.
    DIABETES, 2020, 69
  • [8] Effect of Somatostatin Receptor 2 Antagonism (SSTR2a) on Oral Glucose Tolerance (OGT) in a Rat Model of Type 2 Diabetes (T2D)
    D'Souza, Ninoschka C.
    Aleali, Nadia
    Shakeri, Dorsa
    Hoffman, Emily G.
    Atherley, Sara C.
    Champsi, Sabrina
    El-Zahed, Maya
    Liggins, Richard
    Chan, Owen
    Riddell, Michael C.
    DIABETES, 2023, 72
  • [9] Initiation of Insulin Therapy Improves Self-Reported Diabetes Symptoms in Patients (Pts) with Type 2 Diabetes (T2D) on Oral Agents
    Lee, Lauren J.
    McLeod, Lori
    Nelson, Lauren
    Hill, Cheryl
    Sweeney, Carolyn
    Sun, Peter
    Fahrbach, Jessie
    Martin, Sherry
    Weinstock, Ruth S.
    DIABETES, 2009, 58 : A481 - A481
  • [10] Duodenal Recellularization via Electroporation Therapy (ReCET) and GLP-1 RA to Replace Insulin in T2D Patients-EMINENT Study Six-Month Results
    Busch, Celine B. E.
    Meiring, Suzanne
    Van Baar, Annieke C. G.
    Holleman, Frits
    Nieuwdorp, Max
    Bergman, Jacques J.
    DIABETES, 2023, 72
123